Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.36 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4617880 | 1.00 | RAB9A (0.54) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 | |
| SCHEMBL4337454 | 1.00 | RAB9A (0.54) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 | |
| SCHEMBL29004577 | 1.00 | RAB9A (0.54) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 | |
| SCHEMBL29004578 | 1.00 | RAB9A (0.54) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 | |
| SCHEMBL4337459 | 1.00 | RAB9A (0.54) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 | |
| SCHEMBL13614205 | 1.00 | RAB9A (0.54) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 | |
| SCHEMBL1364978 | 0.94 | RAB9A (0.63) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 | |
| SCHEMBL11907502 | 0.94 | RAB9A (0.63) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 | |
| SCHEMBL11907499 | 0.94 | RAB9A (0.63) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 | |
| SCHEMBL11907503 | 0.94 | RAB9A (0.63) | RAB9AKDM4ENPC1SMN1; SMN2SENP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772544-B2 | Process for the production of bimatoprost | SANDOZ AG (CH) | 2014-07-08 | — | — | US | disclosed |
| WO-2012011128-A1 | PREPARATION OF PROSTAGLANDIN DERIVATIVES | APTUIT LAURUS PRIVATE LIMITED (IN) | 2012-01-26 | — | — | WO | disclosed |
| US-20110178340-A1 | IMPROVED PROCESS FOR THE PRODUCTION OF BIMATOPROST | SANDOZ AG (CH) | 2011-07-21 | — | — | US | disclosed |
| EP-2135860-A1 | Improved process for the production of bimatoprost | Sandoz AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| WO-2009153206-A2 | Improved Process for the Production of Bimatoprost | SANDOZ AG (CH) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178340-A1 | IMPROVED PROCESS FOR THE PRODUCTION OF BIMATOPROST | AVPR2, PTGIR, ADH1A | RAB9A 3681/4885KDM4E 4829/4885NPC1 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.